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LETTER TO THE EDITOR
Severe osteoarticular
involvement in isotretinoin-
triggered acne fulminans: two
cases successfully treated with
anakinra
Editor
Acne fulminans (AF) is a severe form of inflammatory
and ulcerated acne associated with fever, malaise, joint swellings
and polyarthralgia.1 Osteoarticular lesions are often described
and can be radiologically indistinguishable from those observed
in synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO)
syndrome.2,3 SAPHO is an autoinflammatory disease character-
ized by osteoarticular and cutaneous manifestations, the latter
including nodular and fulminans acne, hidradenitis suppurativa
and palmoplantar pustulosis.3 Thus, AF is considered part of the
SAPHO spectrum.1
Oral isotretinoin (13-cis retinoic acid) is recommended for
the treatment of severe nodular acne.4 It has also been used in
AF1 that, paradoxically, can be triggered by isotretinoin.5
We report two male adolescents with isotretinoin-triggered
AF and severe osteoarticular manifestations. In both cases, treat-
ment with a recombinant IL-1 receptor antagonist, anakinra,
bisphosphonates and a short course of corticosteroids led to
rapid disease control.
A 17-year-old male was treated with 0.6 mg/kg/day oral iso-
tretinoin for nodular acne. After 4 weeks, he presented ulcerated
nodules on the face and trunk healing with hypertrophic scars
(Fig. 1), associated with back, chest and hip pain, joint swelling
and functional impairment. Isotretinoin was discontinued.
C-reactive protein was 3.23 mg/dL, ESR 46 mm/h and WBC
count 14 000/lL (neutrophils 83.9%). Whole-body magnetic
resonance imaging (MRI) revealed sternoclavicular joint
involvement extending to the clavicles, soft tissues and sternum,
as well as multiple hyperintense lesions of L2 vertebra, left iliac
crest and left distal femoral metaphysis (Fig. 1). Bone scintigra-
phy showed increased uptake at the same structures (Fig. 1). We
administered prednisone (0.8 mg/kg/day) tapered over 2 weeks,
three pamidronate intravenous infusions (1 mg/kg) and ana-
kinra subcutaneous injections (100 mg/day) for 3 months. A
marked osteoarticular and cutaneous improvement was
observed within 2 weeks, with clinical remission in 1 month
without side-effects. Follow-up MRI documented lesion resolu-
tion and the disease did not recur over the last 3 years.
The second patient, a 17-year-old male, was admitted to our
emergency department for back and chest pain, weight loss and
low-grade fever in the last 10 days. Isotretinoin (0.8 mg/kg/day)
had been administered for severe acne for 6 weeks and stopped
5 days before. Physical examination revealed cystic and ulcerated
acne, reduced hip movement range with sternal and lumbar
spine pain. C-reactive protein was 2.68 mg/dL, ESR 35 mm/h
and WBC count 12 010/lL (71.7% neutrophils). Whole-body
MRI and bone scintigraphy showed sternoclavicular, right
shoulder, sacroiliac and long bone involvement. We adminis-
tered prednisone 2 mg/kg/day, gradually tapered over 8 weeks,
three pamidronate infusions (1 mg/kg) and anakinra (100 mg/
day), with marked reduction of symptoms within 2 weeks. Fol-
low-up MRI and bone scintigraphy performed at 7, 12 and
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Figure 1 Case 1: Confluent papulonodular and cystic inflamma-
tory acne lesions on the right cheek shortly after isotretinoin dis-
continuation (a); residual erythema and scarring in the same areas
after 2-week anakinra treatment (b). Contiguous sagittal and coro-
nal whole-body STIR MR image (c–e) and whole-body bone scan
99mTc-MDP (f). Sternoclavicular involvement extending to the
clavicles, the soft tissues and the sternum (c, arrows). Hyperinten-
sity of the left iliac crest (d, arrow) and adjacent soft tissue, and left
distal femoral metaphysis (d, arrow). L2 vertebra hyperintensity (e,
arrow). Increased radiotracer uptake at the same areas (f, arrows).
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18 months revealed a progressive improvement. Anakinra ther-
apy is still ongoing 2 years after discharge (100 mg every
3 days), without side-effects.
Understanding of SAPHO pathogenesis is still limited. Proin-
flammatory cytokines such as TNF-a and IL-1 seem to play a
central role,6–8 and the recombinant IL-1 receptor antagonist
anakinra has proven rapidly effective in a limited number of
patients with SAPHO syndrome7–10 (Table 1).
Although mild and transient myalgia and arthralgia are fre-
quent during isotretinoin treatment, severe osteoarticular mani-
festations of AF occur rarely, usually within few weeks from
isotretinoin starting.5 This suggests a possible genetic suscepti-
bility to SAPHO.
In conclusion, we describe for the first time the successful use
of anakinra in two cases of AF presenting radiologically docu-
mented osteoarticular manifestations. The rapid and sustained
osteoarticular and acne therapeutic response is in keeping with
the IL-1 role in SAPHO pathogenesis. Of note, the combined
therapy with anakinra and pamidronate allowed to significantly
shorten corticosteroid course.
Bone scintigraphy alterations observed in about 70% of AF
cases2 indicate that the large majority of patients with AF have
SAPHO syndrome. Patients with AF should be systemically
screened by whole-body bone scintigraphy and/or MRI to ascer-
tain osteoarticular lesions, and ensure an appropriate manage-
ment and follow-up.
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Table 1 Cases of SAPHO syndrome treated with anakinra
Patient
number
Age Sex SAPHO skin
manifestation
Previous therapies Response to
treatment (weeks)
Loss of efficacy
and relapses
Adverse
reaction
Reference
1 54 F PPP NSAIDs, CCS, MTX,
LEF
Yes (1) No Yes* 9
2 41 M PPP NSAIDs, CCS,
colchicines, SSZ, retinoids
Yes (<2) No No 9
3 49 F HS NSAIDs, MTX, INFX,
retinoids
Yes (2) No No 9
4 53 F PPP NSAIDs, CCS, MTX,
colchicines, INFX,
ETN, ADA
Yes (4) No No 9
5 25 F PPP NSAIDs, pamidronate Yes (2) No No 9
6 37 M PPP NSAIDs, pamidronate,
ETN, ADA
No No No 9
7 47 F PPP SSZ Yes (8) No No 8
8 NS NS PPP NSAIDs, CCS, LEF, MTX,
pamidronate, tetracyclines,
INFX, ETN, ADA
Yes (rapid action) No Yes* 7
CCS, corticosteroids; MTX, methotrexate; LEF, leflunomide; SSZ, sulfasalazine; INFX, infliximab; ETN, etanercept; ADA, adalimumab; PPP, palmoplantar
pustulosis; HS, hidradenitis suppurativa; NS, not specified.
*Injection site reaction.
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